Genocea Biosciences Inc (GNCAQ)

[jondoeuk]

NCI cell therapy workshop (Day one) https://nci.rev.vbrick.com/#/videos/8d310e18-6ec4-441a-b668-9fb2177f712f

9:00am – 9:15am EST
NCI Welcome
James Doroshow, MD
Rose Aurigemma, PhD
Marc Ernstoff, MD

9:15am – 11:45pm EST
Choosing the Target: Specificity and Toxicity
Chair: Madhav Dhodapkar, MBBS (Emory University)

9:15am – 9:45am, Selecting and Validating Targets, Isolating High Affinity TCRs, and Engineering T Cells That Can Be Effective in Therapy, Philip Greenberg, MD (Fred Hutchinson Cancer Research Center)

9:45am – 10:15am, Development of Combinatorial Antigen Sensing T Cell Therapeutics for Solid Tumors, Kole Roybal, PhD (University of California, San Francisco)

10:15am – 10:45am, Targeting Solid Malignancies With “Public” Neoantigen-Specific T Cell Receptors, Christopher Klebanoff, MD (Memorial Sloan Kettering Cancer Center)

10:45am – 11:15am, Safety and Clinical Activity of Engineered TCR-T Cells for HPV-Associated Cancers, Christian Hinrichs, MD (National Cancer Institute)

Panel Discussion
Laronna Colbert, MD (Food and Drug Administration)
Madhav Dhodapkar, MBBS (Emory University)
Philip Greenberg, MD (Fred Hutchinson Cancer Research Center)
Christian Hinrichs, MD (National Cancer Institute)
Christopher Klebanoff, MD (Memorial Sloan Kettering Cancer Center)
Wendell Lim, PhD (University of California, San Francisco)
Kole Roybal, PhD (University of California, San Francisco)

11:45am – 12:30pm EST
Keynote Talk

Approaches to Augment Potency of CAR T Cell Therapies, Crystal Mackall, MD (Stanford University)

12:30pm – 1:00pm EST
Break

1:00pm – 3:30pm EST
Reaching the Target: Modulating the Tumor Microenvironment
Chair: Yvonne Chen, PhD (University of California, Los Angeles)

1:00pm – 1:30pm, Feast to Famine: Preparing Therapeutic T Cells for Intratumoral Function Through Metabolic Reprogramming, Greg Delgoffe, PhD (University of Pittsburgh)

1:30pm – 2:00pm, Armored CAR T Cells and Solid Tumor Malignancies, Renier Brentjens, MD, PhD (Memorial Sloan Kettering Cancer Center)

2:00pm – 2:30pm, Enhancing Cell Therapies by Overcoming TGFß in the TME, Catherine Bollard, MD, MBChB (Children’s National Research Institute and George Washington University)

2:30pm – 3:00pm, Does It Make Sense to Add Immune Checkpoint Blockade to Adoptive Cell Transfer Therapies? Antoni Ribas, MD, PhD (University of California, Los Angeles)

Panel Discussion
Catherine Bollard, MD, MBChB (Children’s National Research Institute)
Renier Brentjens, MD, PhD (Memorial Sloan Kettering Cancer Center)
Yvonne Chen, PhD (University of California, Los Angeles)
Greg Delgoffe, PhD (University of Pittsburgh)
Michael Hudecek, MD (Universitätsklinikum Würzburg, Germany)
Antoni Ribas, MD, PhD (University of California, Los Angeles)
Cliona Rooney, PhD (Baylor College of Medicine)

3:30pm – 4:00pm EST
Break

4:00pm – 6:30pm EST
Immune Cell Fitness and Persistence
Chair: Alex Marson, MD, PhD (University of California, San Francisco)

4:00pm – 4:30pm, The Tug-o-War Between CAR T and Solid Tumors, Carl June, MD (University of Pennsylvania)

4:30pm – 5:00pm, Driving CAR T Cells into Solid Tumors Without Exhaust(ion), Stanley Riddell, MD (Fred Hutchinson Cancer Research Center)

5:00pm – 5:30pm, Decoding T Cell Dysfunction in Solid Tumors, Andrea Schietinger, PhD (Memorial Sloan Kettering Cancer Center)

5:30pm – 6:00pm, Decoding and Reprogramming T Cell Fitness with CRISPR, Alex Marson, MD, PhD (University of California, San Francisco)

Panel Discussion
Ananda Goldrath, PhD (University of California, San Diego)
Carl June, MD (University of Pennsylvania)
Wendell Lim, PhD (University of California, San Francisco)
Alex Marson, MD, PhD (University of California, San Francisco)
Stanley Riddell, MD (Fred Hutchinson Cancer Research Center)
Andrea Schietinger, PhD (Memorial Sloan Kettering Cancer Center)